O retorno do bolus com Joanne e Marcela falando sobre AAS na profilaxia primária para doença cardiovascular (DCV)! Elas abordam 3 tópicos: - História de AAS na prevenção de DCV - Recomendação atual e os principais estudos que motivaram a mudança de recomendação (ASPREE, ARRIVE E ASCEND) - O que fazer com quem já usa? Tá imperdível! Referências: 1. Aimo A, De Caterina R. Aspirin for primary prevention of cardiovascular disease: Advice for a decisional strategy based on risk stratification. Anatol J Cardiol. 2020;23(2):70-78. 2. Berger JS. Aspirin for Primary Prevention—Time to Rethink Our Approach. JAMA Netw Open.2022;5(4):e2210144. 3. Bowman L, et al. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. N Engl J Med 2018; 379:1529-1539 4. Chiang KF, Shah SJ, Stafford RS. A Practical Approach to Low-Dose Aspirin for Primary Prevention. JAMA. 2019;322(4):301-302 5. Gaziano JM, et al. Aspirin to Reduce Risk of Initial Vascular Events - ARRIVE. Lancet 2018; 392: 1036–46 6. McNeil JJ, et al. Effect of Aspirin on All-Cause Mortality in the Healthy Elderly. N Engl J Med 2018; 379:1519-1528 7. Précoma DB, Oliveira GMM, Simão AF, Dutra OP, Coelho OR, Izar MCO, Póvoa RMS, et al. Atualização da Diretriz de Prevenção Cardiovascular da Sociedade Brasileira de Cardiologia – 2019. Arq. Bras. Cardiol. 2019;113(4):787-891 8. Raber I, et al. The rise and fall of aspirin in the primary prevention of cardiovascular disease. Lancet 2019; 393: 2155–67 9. US Preventive Services Task Force. Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement. JAMA.2022;327(16):1577–1584.